Eisai (ESALY) and Biogen (BIIB) announced that the Biologics License Application for lecanemab, an investigational anti-amyloid beta protofibril antibody, has been designated for Priority Review by the National Medical Products Administration in China. The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened. In China, Eisai initiated submission of data for the BLA to the NMPA in December 2022. Eisai initially submitted a package that includes data from the Phase II clinical trial and the top-line data of the large global Phase III Clarity AD study in mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed Abeta accumulation in the brain. Eisai will submit additional data including full data of the Clarity AD study, as directed by the NMPA.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
- Biogen price target lowered to $333 from $359 at RBC Capital
- Biogen price target raised to $315 from $300 at Cowen
- Biogen price target raised to $351 from $345 at Morgan Stanley
- Biogen price target lowered to $310 from $320 at Oppenheimer